Abeona Therapeutics
ABEO
40 hedge funds and large institutions have $28.5M invested in Abeona Therapeutics in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
687% more capital invested
Capital invested by funds: $3.62M → $28.5M (+$24.8M)
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
67% more funds holding
Funds holding: 24 → 40 (+16)
27.41% more ownership
Funds ownership: 20.06% → 47.47% (+27%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.3M |
| 2 |
AC
Armistice Capital
New York
|
+$4.14M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$4.07M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.78M |
| 5 |
DM
Deerfield Management
New York
|
+$3.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$269K |
| 2 |
CT
Cambridge Trust
Cambridge,
Massachusetts
|
-$243K |
| 3 |
Renaissance Technologies
New York
|
-$20.6K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$11K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$1.47K |
ABEO Hedge Fund Activity: Q4 2022 in Review
40 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2022, worth a combined $28.5M — up 687% from $3.62M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABEO positions and 3 closed out — a net gain of 17 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.3M. The largest seller was Knoll Capital Management, exiting entirely with an estimated $269K sold.
- 40 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2022, up from 24 in Q3 2022.
- Funds reported $28.5M of Abeona Therapeutics stock for Q4 2022, up 687% quarter-over-quarter.
- 20 funds opened new Abeona Therapeutics positions in Q4 2022 and 3 closed out, a net change of +17 holders.
- The largest Abeona Therapeutics buyer in Q4 2022 was Point72 Asset Management, an estimated $4.3M added.
- The largest Abeona Therapeutics seller in Q4 2022 was Knoll Capital Management, an estimated $269K sold.
Based on aggregated 13F filings for Q4 2022.